Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024
Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024
Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …

News

Eli Lilly increases manufacturing investment to $9bn at new Indiana site

May 28, 2024
Manufacturing and Production Diabetes, Eli Lilly, Indiana, investment, manufacturing

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with …

News

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024
Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …

News

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024
Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies

Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …

News

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024
Business Services Biogen, HI-Bio, Immunology, acquisition, immunology

BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …

News

Merck to acquire Mirus Bio for $600m

May 23, 2024
Business Services Merck, Pharmacy, acquisition, gene therapies

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

News

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024
Alexion, Pharmafocus, Rare Diseases, clinical trials, feature

Ahead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices …

Feature

Sustainability in pharma

May 22, 2024
Pharmacy, Pharmafocus, feature, sustainability

Betsy Goodfellow from Pharmafocus considers the need for sustainable practices in the pharma industry and assesses various sustainable advances that have already …

Feature

Sanofi, Formation Bio and OpenAI enter AI collaboration

May 22, 2024
Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …

News

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024
Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …

News

GSK shares positive results from phase 3 asthma trials

May 21, 2024
Research and Development Asthma & COPD, GSK, asthma, clinical trial

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024
Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …

News

AstraZeneca to build $1.5bn ADC facility in Singapore

May 20, 2024
Manufacturing and Production ADCs, AstraZeneca, Oncology, antibody drug conjugate, manufacturing

AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), …

News

ERS Genomics and IRBM sign license agreement for CRISPR/Cas9

May 20, 2024
Research and Development CRISPR/Cas9, ERS Genomics, IRBM, License Agreement, Pharmacy

ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to …

News

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024
Medical Communications Amgen, FDA, Oncology, lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …

News
diana-polekhina-zbsthwt9vlc-unsplash_2

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024
Research and Development AstraZeneca, COVID-19, Immunology, clinical trial

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …

News

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024
Research and Development AMR, Fleming Initiative, GSK, Microbiology, funding

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …

News

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024
Research and Development NeuroSense, Neurology, als, clinical trials

NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …

News

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024
Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …

News

Latest content

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024

Eli Lilly increases manufacturing investment to $9bn at new Indiana site

May 28, 2024

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024